Navigation Links
Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

TARRYTOWN, N.Y., Dec. 20, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time on Monday, December 20, to discuss results of the Phase 3 COPERNICUS study with VEGF Trap-Eye in central retinal vein occlusion (CRVO) and the week 52 follow-up results of the Phase 2 DA VINCI study in patients with diabetic macular edema (DME).  A press release will be issued prior to the call.

Teleconference/Webcast Details To participate in the live call on Monday, December 20, at 8:30 a.m. Eastern Time, please dial (877) 390-5538 for domestic callers and (408) 940-3843 for international callers, participant code 33105543.  The live conference call is being webcast and it can be accessed on the "Newsroom" page of the Company's web site, www.regeneron.com.  The webcast will be available for 30 days following the call.About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com. Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Christine A. Poon Elected to Regeneron Board of Directors
2. Regeneron Announces Presentation at the 2010 Credit Suisse Annual Healthcare Conference
3. Regeneron Announces Presentation at the 17th Annual NewsMakers in the Biotech Industry Conference
4. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
5. Regeneron Increases Size of Public Offering of Common Stock
6. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
7. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
8. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
11. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 2016  CVS Health, the nation,s largest pharmacy innovation ... score of 100 percent on the Corporate Equality Index ... an annual national benchmarking survey and report on corporate ... the Human Rights Campaign Foundation. "Our ... colleagues, customers and suppliers bring to CVS Health," said ...
(Date:12/5/2016)... 2016  New research by the CVS Health ... the U.S. Department of Health and Human Services, ... Response (ASPR), published online today in JAMA ... encourage patients with chronic conditions to refill medications ... also affirms that public-private partnerships can facilitate timely ...
(Date:12/5/2016)... 5, 2016 For the third consecutive year, ... Human Rights Campaign Foundation,s (HRC) annual ... national benchmarking tool used to rate companies on policies ... employee equality. For the last 15 years, ... gauge their equality efforts, culture and business practices. The ...
Breaking Medicine Technology:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... advisory organization, is proud to announce it has added CXC Solutions (CXC) as ... management solutions. These solutions are tailored to help benefits advisors reduce operating ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... portal for all the knowledge resources, including white papers, guides, handbooks, case studies, ... , To access more than 9,000 documents, webinars and videos available online, ...
(Date:12/6/2016)... ... December 06, 2016 , ... “Tatiana Sibirskaya: A Life ... story of sacrifice and enlightenment. , “Tatiana Sibirskaya: A Life Devoted ... looking for creative outlets, Carolyn gravitated toward writing through the inspiration of her ...
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) ... 125 for their industry leading training methods that engage their associates and link ... the global elite in employer-sponsored training and development programs. , “The 2017 Training ...
(Date:12/5/2016)... ... December 06, 2016 , ... For many years, Andrew G. Zubinas ... thin. The beauty of the Lithuanian language and its poetry inspired him ... book, Zubinas lyrically explores all aspects of a living, breathing forest where nothing ever ...
Breaking Medicine News(10 mins):